

# John L Gore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758900/publications.pdf>

Version: 2024-02-01

254  
papers

7,794  
citations

57758

44  
h-index

62596

80  
g-index

257  
all docs

257  
docs citations

257  
times ranked

8865  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 74-84.	1.9	917
2	Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. <i>Cancer</i> , 2007, 110, 1493-1500.	4.1	482
3	Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1629.	7.4	351
4	Global Burden of Urologic Cancers, 1990–2013. <i>European Urology</i> , 2017, 71, 437-446.	1.9	248
5	Use of Radical Cystectomy for Patients With Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 802-811.	6.3	246
6	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. <i>Cancer</i> , 2007, 109, 2239-2247.	4.1	236
7	Mortality increases when radical cystectomy is delayed more than 12 weeks. <i>Cancer</i> , 2009, 115, 988-996.	4.1	223
8	Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies. <i>Annals of Internal Medicine</i> , 2013, 158, 145.	3.9	144
9	The burden of bladder cancer care. <i>Current Opinion in Urology</i> , 2014, 24, 487-491.	1.8	138
10	Survivorship Beyond Convalescence: 48-Month Quality-of-Life Outcomes After Treatment for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 888-892.	6.3	132
11	Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2017, 197, 1189-1199.	0.4	128
12	Risk Factors for Renal Cell Carcinoma in the VITAL Study. <i>Journal of Urology</i> , 2013, 190, 1657-1661.	0.4	123
13	Variations in reconstruction after radical cystectomy. <i>Cancer</i> , 2006, 107, 729-737.	4.1	121
14	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1387-1405.	2.5	117
15	Implementing Telemedicine in Response to the COVID-19 Pandemic. <i>Journal of Urology</i> , 2020, 204, 14-16.	0.4	96
16	Impact of a Bladder Cancer Diagnosis on Smoking Behavior. <i>Journal of Clinical Oncology</i> , 2012, 30, 1871-1878.	1.6	90
17	Expected population impacts of discontinued prostate-specific antigen screening. <i>Cancer</i> , 2014, 120, 3519-3526.	4.1	90
18	Treatment of muscle-invasive bladder cancer: A systematic review. <i>Cancer</i> , 2016, 122, 842-851.	4.1	85

#	ARTICLE	IF	CITATIONS
19	Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2017, 197, 548-558.	0.4	84
20	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 776-785.	10.7	82
21	Urinary diversion and morbidity after radical cystectomy for bladder cancer. <i>Cancer</i> , 2010, 116, 331-339.	4.1	80
22	Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy. <i>World Journal of Urology</i> , 2009, 27, 45-50.	2.2	74
23	Hospice Use and High-Intensity Care in Men Dying of Prostate Cancer. <i>Archives of Internal Medicine</i> , 2011, 171, 204.	3.8	66
24	Quality of life in women undergoing urinary diversion for bladder cancer: results of a multicenter study among long-term disease-free survivors. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 43.	2.4	66
25	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROIMPACT study. <i>Cancer</i> , 2017, 123, 2850-2859.	4.1	66
26	Marriage and mortality in bladder carcinoma. <i>Cancer</i> , 2005, 104, 1188-1194.	4.1	65
27	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <i>JAMA Oncology</i> , 2016, 2, 890.	7.1	65
28	Influence of Publication of US and European Prostate Cancer Screening Trials on PSA Testing Practices. <i>Journal of the National Cancer Institute</i> , 2011, 103, 520-523.	6.3	57
29	Perinephric Fat Thickness Is an Independent Predictor of Operative Complexity During Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2014, 28, 587-591.	2.1	57
30	Sexual Orientation and Testing for Prostate and Colorectal Cancers Among Men in California. <i>Medical Care</i> , 2008, 46, 1240-1248.	2.4	55
31	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. <i>European Urology Oncology</i> , 2018, 1, 292-304.	5.4	54
32	Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 94.	2.4	53
33	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 5471-5478.	7.0	52
34	Design and feasibility of integrating personalized PRO dashboards into prostate cancer care. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 38-47.	4.4	52
35	Correlates of Bother Following Treatment for Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2010, 184, 1309-1315.	0.4	50
36	A National Study of Trauma Level Designation and Renal Trauma Outcomes. <i>Journal of Urology</i> , 2012, 187, 536-541.	0.4	50

#	ARTICLE	IF	CITATIONS
37	The Costs of Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 261-269.	1.8	50
38	Partnership status influences quality of life in low-income, uninsured men with prostate cancer. <i>Cancer</i> , 2005, 104, 191-198.	4.1	49
39	Use and Outcomes of Extended Antibiotic Prophylaxis in Urological Cancer Surgery. <i>Journal of Urology</i> , 2014, 192, 425-429.	0.4	49
40	PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. <i>Cancer</i> , 2018, 124, 2733-2739.	4.1	49
41	Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. <i>World Journal of Urology</i> , 2011, 29, 73-77.	2.2	48
42	Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study. <i>Journal of Urology</i> , 2018, 199, 1023-1031.	0.4	48
43	Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt367-djt367.	6.3	47
44	Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 505.e9-505.e13.	1.6	46
45	Readmissions in the postoperative period following urinary diversion. <i>World Journal of Urology</i> , 2011, 29, 79-84.	2.2	45
46	Overuse of Antimicrobial Prophylaxis in Community Practice Urology. <i>Journal of Urology</i> , 2015, 193, 543-547.	0.4	44
47	Delays in radical cystectomy for muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 2011-2017.	4.1	44
48	Telemedicine and eConsults for Hospitalized Patients During COVID-19. <i>Urology</i> , 2020, 141, 12-14.	1.0	44
49	Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1412-1417.	5.0	43
50	User-centered design of quality of life reports for clinical care of patients with prostate cancer. <i>Surgery</i> , 2014, 155, 789-796.	1.9	43
51	Downstream Complications Following Urinary Diversion. <i>Journal of Urology</i> , 2013, 190, 916-922.	0.4	42
52	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 623-628.	2.8	41
53	The Morbidity of Ureteral Strictures in Patients with Prior Ureteroscopic Stone Surgery: Multi-Institutional Outcomes. <i>Journal of Endourology</i> , 2018, 32, 309-314.	2.1	41
54	Relevance of graph literacy in the development of patient-centered communication tools. <i>Patient Education and Counseling</i> , 2016, 99, 448-454.	2.2	39

#	ARTICLE	IF	CITATIONS
55	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
56	AUA White Paper on Implementation of Shared Decision Making into Urological Practice. <i>Urology Practice</i> , 2016, 3, 355-363.	0.5	38
57	Knowledge of the harms of tobacco use among patients with bladder cancer. <i>Cancer</i> , 2014, 120, 3914-3922.	4.1	37
58	Implementation of a "real-world" learning health care system: Washington state's Comparative Effectiveness Research Translation Network (CERTAIN). <i>Surgery</i> , 2014, 155, 860-866.	1.9	37
59	Patient-centered prioritization of bladder cancer research. <i>Cancer</i> , 2018, 124, 3136-3144.	4.1	36
60	Erectile Aid Use by Men Treated for Localized Prostate Cancer. <i>Journal of Urology</i> , 2009, 182, 649-654.	0.4	35
61	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. <i>Advances in Urology</i> , 2013, 2013, 1-6.	1.3	34
62	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	1.9	34
63	The effect of postprostatectomy external beam radiotherapy on quality of life. <i>Cancer</i> , 2006, 107, 281-288.	4.1	32
64	Disparities in Access and Regionalization of Care in Testicular Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e785-e793.	1.9	32
65	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. <i>European Urology</i> , 2022, 82, 341-351.	1.9	32
66	Laparoscopic Versus Open Renal Procurement for Pediatric Recipients of Living Donor Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2514-2520.	4.7	31
67	Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. <i>Urology</i> , 2015, 86, 262-268.	1.0	31
68	Comparative Effectiveness of a Patient Centered Pathology Report for Bladder Cancer Care. <i>Journal of Urology</i> , 2016, 196, 1383-1389.	0.4	30
69	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436.	2.5	30
70	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 295-302.	3.9	30
71	Case Report: Avoidance of Palpable Corporal Fibrosis Due to Priapism with Upregulators of Nitric Oxide. <i>Journal of Sexual Medicine</i> , 2006, 3, 173-176.	0.6	29
72	National Trends in Secondary Procedures Following Pediatric Pyeloplasty. <i>Journal of Urology</i> , 2016, 195, 1209-1214.	0.4	29

#	ARTICLE	IF	CITATIONS
73	Preliminary Comparative Effectiveness of Robotic Versus Open Radical Cystectomy in Elderly Patients. <i>Journal of Endourology</i> , 2016, 30, 212-217.	2.1	29
74	Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. <i>Journal of Urology</i> , 2022, 207, 779-788.	0.4	29
75	Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2019, 154, e191629.	4.3	28
76	Hospital-level variation in the quality of urologic cancer surgery. <i>Cancer</i> , 2012, 118, 987-996.	4.1	27
77	Identification of underserved areas for urologic cancer care. <i>Cancer</i> , 2014, 120, 1565-1571.	4.1	27
78	National Trends in Followup Imaging after Pyeloplasty in Children in the United States. <i>Journal of Urology</i> , 2015, 194, 777-782.	0.4	27
79	Health Related Quality of Life Following Radical Cystectomy: Comparative Analysis from the Medicare Health Outcomes Survey. <i>Journal of Urology</i> , 2018, 199, 669-675.	0.4	27
80	Readability of Health Related Quality of Life Instruments in Urology. <i>Journal of Urology</i> , 2010, 183, 1977-1981.	0.4	26
81	Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial. <i>Journal of the National Cancer Institute</i> , 2013, 105, 546-550.	6.3	26
82	Neonatal Circumcision and Urinary Tract Infections in Infants With Hydronephrosis. <i>Pediatrics</i> , 2018, 142, .	2.1	26
83	Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. <i>Journal of the American College of Surgeons</i> , 2017, 224, 270-275e1.	0.5	25
84	Root Causes and Modifiability of 30-Day Hospital Readmissions after Radical Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2016, 195, 894-899.	0.4	24
85	Partnership and outcomes in men with prostate cancer. <i>Cancer</i> , 2009, 115, 4688-4694.	4.1	23
86	Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports. <i>Human Pathology</i> , 2014, 45, 2192-2201.	2.0	22
87	High Regional Variation in Urethroplasty in the United States. <i>Journal of Urology</i> , 2015, 193, 179-183.	0.4	22
88	Patient-centered risk stratification of disposition outcomes following radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e17-235.e23.	1.6	22
89	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1336-1342.	6.3	22
90	Initial Experience with Laparoscopically Assisted Percutaneous Cryotherapy of Renal Tumors. <i>Journal of Endourology</i> , 2005, 19, 480-483.	2.1	21

#	ARTICLE	IF	CITATIONS
91	Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study. <i>Journal of Urology</i> , 2018, 200, 397-404.	0.4	21
92	MENTAL HEALTH OF LOW INCOME UNINSURED MEN WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 173, 1323-1326.	0.4	20
93	Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 287-291.	1.9	20
94	Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019, 202, 1136-1142.	0.4	20
95	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	2.1	19
96	Ureteral tumor thrombus from renal cell carcinoma extending into bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 393-395.	1.6	18
97	Readability of urologic pathology reports: The need for patient-centered approaches. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1091-1094.	1.6	18
98	A national cross-sectional survey of financial toxicity among bladder cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 76.e1-76.e7.	1.6	17
99	Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects. <i>Medical Care</i> , 2015, 53, 79-86.	2.4	16
100	Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients. <i>Urology</i> , 2016, 91, 70-76.	1.0	16
101	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.	5.4	16
102	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.4	16
103	Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors. <i>Urology</i> , 2021, 153, 236-243.	1.0	16
104	Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. <i>Urology</i> , 2018, 113, 146-152.	1.0	15
105	Practice Patterns for Women With Overactive Bladder Syndrome: Time Between Medications and Third-Line Treatments. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 431-436.	1.1	15
106	Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2019, 202, 585-591.	0.4	15
107	Improved Continence in Patients With Neurogenic Sphincteric Incompetence With Combination Tubularized Posterior Urethroplasty and Fascial Wrap: The Lengthening, Narrowing and Tightening Procedure. <i>Journal of Urology</i> , 2010, 184, 1763-1767.	0.4	14
108	Use of medical expulsive therapy in children: An assessment of nationwide practice patterns and outcomes. <i>Journal of Pediatric Urology</i> , 2017, 13, 509.e1-509.e7.	1.1	14

#	ARTICLE	IF	CITATIONS
109	The Socioeconomic Status of Donors and Recipients of Living Unrelated Renal Transplants in the United States. <i>Journal of Urology</i> , 2012, 187, 1760-1765.	0.4	13
110	Improving bladder cancer patient care: a pharmacoeconomic perspective. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 661-668.	2.4	13
111	Persistent, Unexplained Leukocytosis Is a Paraneoplastic Syndrome Associated With a Poor Prognosis in Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e253-e258.	1.9	13
112	Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor. <i>International Journal of Surgical Pathology</i> , 2020, 28, 80-86.	0.8	13
113	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	1.9	13
114	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 796.e1-796.e6.	1.6	13
115	Does the Diagnosis of Bladder Cancer Lead to Higher Rates of Smoking Cessation? Findings from the Medicare Health Outcomes Survey. <i>Journal of Urology</i> , 2019, 202, 241-246.	0.4	13
116	Perineocele: Symptom complex, description of anatomic defect, and surgical technique for repair. <i>Urology</i> , 2006, 67, 265-268.	1.0	12
117	Outcomes in Men Denied Access to a California Public Assistance Program for Prostate Cancer. <i>Public Health Reports</i> , 2007, 122, 217-223.	2.5	12
118	Burden and timing of venothrombotic events in patients younger than 65 years undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 815-819.	1.6	12
119	Underuse and underreporting of smoking cessation for smokers with a new urologic cancer diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e1-504.e7.	1.6	11
120	Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence. <i>Urology</i> , 2019, 125, 146-153.	1.0	11
121	Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 324-330.	1.6	11
122	Metformin effects on biochemical recurrence and metabolic signaling in the prostate. <i>Prostate</i> , 2015, 75, 1694-1703.	2.3	10
123	The impact of smoking on radical cystectomy complications increases in elderly patients. <i>Cancer</i> , 2021, 127, 1387-1394.	4.1	10
124	Using a multilevel implementation strategy to facilitate the screening and treatment of tobacco use in the outpatient urology clinic: A prospective hybrid type I study. <i>Cancer</i> , 2022, 128, 1184-1193.	4.1	10
125	Obesity and Renal Transplantation: Is Bariatric Surgery the Answer?. <i>Transplantation</i> , 2009, 87, 1115.	1.0	9
126	Trends in Followup Imaging after Adult Pyeloplasty. <i>Journal of Urology</i> , 2014, 191, 1357-1362.	0.4	9

#	ARTICLE	IF	CITATIONS
127	Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 210-213.	1.9	9
128	Inferring bladder cancer research prioritization from patient-generated online content. <i>World Journal of Urology</i> , 2019, 37, 1145-1150.	2.2	9
129	The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 144-150.	3.9	9
130	“Help me figure this out”: Qualitative explorations of patient experiences with cancer pathology reports. <i>Patient Education and Counseling</i> , 2021, 104, 40-44.	2.2	9
131	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. <i>Value in Health</i> , 2021, 24, 1111-1117.	0.3	9
132	Patient and public involvement in the design and conduct of a large, pragmatic observational trial to investigate recurrent, high-risk non-muscle-invasive bladder cancer. <i>Cancer</i> , 2022, 128, 103-111.	4.1	9
133	Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa098.	2.9	9
134	Thromboembolic Complications of Sling Surgery for Stress Urinary Incontinence Among Female Medicare Beneficiaries. <i>Urology</i> , 2009, 74, 1223-1226.	1.0	8
135	Comparison of Selective Parenchymal Clamping to Hilar Clamping During Robotic-assisted Laparoscopic Partial Nephrectomy. <i>Urology</i> , 2014, 83, 339-344.	1.0	8
136	Active surveillance for prostate cancer: the role of the pathologist. <i>Pathology</i> , 2015, 47, 1-3.	0.6	8
137	15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e1-530.e7.	1.6	8
138	OPTIMAL COMBINATIONS OF SYSTEMATIC SEXTANT AND LATERALLY DIRECTED BIOPSIES FOR THE DETECTION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2001, , 1554-1559.	0.4	8
139	Androgen Deficiency in the Etiology and Treatment of Erectile Dysfunction. <i>Urologic Clinics of North America</i> , 2005, 32, 457-468.	1.8	7
140	Patient-centered approaches to creating understandable health information. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 559-563.	1.6	7
141	Comparative effectiveness of a pilot patient-centered ultrasound report in the management of hydronephrosis. <i>Journal of Pediatric Urology</i> , 2018, 14, 57.e1-57.e7.	1.1	7
142	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019, 5, 289-298.	0.4	7
143	What Goes Up Must Come Down: Identifying Truth from Global Prostate Cancer Epidemiology. <i>European Urology</i> , 2020, 77, 53-54.	1.9	7
144	Patient empowerment through engagement in bladder cancer research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 193.e13-193.e19.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 65-68.	1.6	7
146	Specificity of radiographic lymphadenopathy for lymph node metastasis in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 442-442.	1.6	7
147	Follow-up imaging after acute evaluations for pediatric nephrolithiasis: Trends from a National database. <i>Journal of Pediatric Urology</i> , 2018, 14, 525-531.	1.1	6
148	Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 732.e9-732.e16.	1.6	6
149	Variable Resource Utilization in the Prenatal and Postnatal Management of Isolated Hydronephrosis. <i>Urology</i> , 2017, 108, 155-160.	1.0	6
150	Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC). <i>Journal of Clinical Oncology</i> , 2019, 37, e16007-e16007.	1.6	6
151	Spending and Out-of-Pocket Costs for Genital Gender-Affirming Surgery in the US. <i>JAMA Surgery</i> , 2022, 157, 799.	4.3	6
152	Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 9.e19-9.e27.	1.6	5
153	Litmus test or destination systemic therapy? Trends in referral for surgery after initial systemic therapy in metastatic kidney cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 502-502.	1.6	5
154	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 263-279.	3.8	5
155	Laparoscopic partial nephrectomy and minimally invasive nephronsparing surgery. <i>Current Urology Reports</i> , 2003, 4, 13-20.	2.2	4
156	Accessing complex urologic surgery in the 21st century. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 379-382.	1.6	4
157	Patient-Centered Outcomes in Bladder Cancer. <i>Current Urology Reports</i> , 2018, 19, 105.	2.2	4
158	Beyond classic risk adjustment: Socioeconomic status and hospital performance in urologic oncology surgery. <i>Cancer</i> , 2018, 124, 3372-3380.	4.1	4
159	Modeling recovery curves with application to prostatectomy. <i>Biostatistics</i> , 2019, 20, 549-564.	1.5	4
160	Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015. <i>Urology</i> , 2021, 149, 154-160.	1.0	4
161	Integration of Mental Health Metrics into Patient-centered Care of Urology Patients. <i>European Urology Focus</i> , 2020, 6, 1147-1149.	3.1	4
162	Optimizing Outcomes in Urological Surgery: Postoperative Care. <i>Urology Practice</i> , 2020, 7, 521-529.	0.5	4

#	ARTICLE	IF	CITATIONS
163	Patterns of questionable quality care in nonmuscle invasive bladder cancer. <i>Cancer</i> , 2010, 116, 2508-2510.	4.1	3
164	Adoption of Laparoscopic Radical Nephrectomy in the State of Washington. <i>Urology</i> , 2012, 79, 326-331.	1.0	3
165	Hospital-level Variation in the Quality of Benign Inpatient Urologic Surgery. <i>Urology</i> , 2016, 87, 82-87.	1.0	3
166	Incorporating the Patient into Urologic Cancer Research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 546-547.	1.6	3
167	Understanding the Economic Burden of Treating Low-Grade Upper Tract Urothelial Cancer in the United States. <i>Urology Practice</i> , 2021, 8, 1-7.	0.5	3
168	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
169	High-intensity end-of-life care among Medicare beneficiaries with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e17-731.e24.	1.6	3
170	Strategies to Optimize Nephrolithiasis Emergency Care (STONE): Prospective Evaluation of an Emergency Department Clinical Pathway. <i>Urology</i> , 2022, 160, 60-68.	1.0	3
171	The impact of physician specialty on general and bladder cancer-specific quality of life among patients with muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-462.	1.6	3
172	Bladder cancer caregiver quality of life and patient cancer severity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 456-456.	1.6	3
173	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100858.	1.2	3
174	Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation. <i>European Urology Open Science</i> , 2022, 39, 79-82.	0.4	3
175	Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon. <i>Urology Case Reports</i> , 2016, 4, 36-37.	0.3	2
176	The impact of readmission hospital on failure-to-rescue rates following major urologic cancer surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 156.e1-156.e7.	1.6	2
177	Can We Prevent Bladder Cancer Recurrences?. <i>European Urology</i> , 2019, 75, 602-603.	1.9	2
178	Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 236.e9-236.e20.	1.6	2
179	Discharge Opioid Prescription Patterns After Kidney Cancer Surgery. <i>Urology</i> , 2021, 153, 228-235.	1.0	2
180	487: Trends in Reconstruction after Radical Cystectomy in the Medicare Population. <i>Journal of Urology</i> , 2005, 173, 133-134.	0.4	2

#	ARTICLE	IF	CITATIONS
181	Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.. Journal of Clinical Oncology, 2013, 31, 267-267.	1.6	2
182	Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 112-112.	1.6	2
183	Association of persistent, unexplained leukocytosis, a paraneoplastic syndrome, with poor prognosis in patients with urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2013, 31, 291-291.	1.6	2
184	Impact of bladder cancer stage on work impairment and financial toxicity.. Journal of Clinical Oncology, 2020, 38, 460-460.	1.6	2
185	Associations of self-efficacy, social support and coping strategies with health-related quality of life after radical cystectomy for bladder cancer: A cross-sectional study. European Journal of Cancer Care, 2022, , .	1.5	2
186	A Patient-Centered Approach to Research Prioritization in Prostate Cancer. Journal of Urology, 2022, 208, 277-283.	0.4	2
187	Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nature Reviews Urology, 2006, 3, 449-452.	1.4	1
188	Editorial Comment. Urology, 2011, 78, 1113-1114.	1.0	1
189	MP15-20 SURGICAL PATHOLOGY AND THE PATIENT: A SYSTEMATIC REVIEW EVALUATING THE PRIMARY AUDIENCE OF PATHOLOGY REPORTS. Journal of Urology, 2014, 191, .	0.4	1
190	Author Reply. Urology, 2016, 87, 87.	1.0	1
191	Editorial Comment. Urology, 2018, 116, 74-75.	1.0	1
192	Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. European Urology Open Science, 2020, 19, 27-36.	0.4	1
193	Association of the 2012 American Urological Association Vasectomy Guidelines with National Trends in Vasectomy Followup in the United States. Urology Practice, 2021, 8, 226-231.	0.5	1
194	Well-being and Perceptions of Supportive Resources among Caregivers of Patients with Bladder Cancer. Bladder Cancer, 2021, 7, 43-52.	0.4	1
195	Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer. Urology Practice, 2021, 8, 348-354.	0.5	1
196	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e1-496.e8.	1.6	1
197	A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 595-601.	1.6	1
198	Hospital re-admission patterns and outcomes following major urologic cancer surgery.. Journal of Clinical Oncology, 2015, 33, 497-497.	1.6	1

#	ARTICLE	IF	CITATIONS
199	Creating patient engagement infrastructure in bladder cancer research prioritization.. Journal of Clinical Oncology, 2016, 34, e18168-e18168.	1.6	1
200	An update on penile cancer: Evaluating management trends and clinical outcomes using the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 492-492.	1.6	1
201	Comparative effectiveness of a patient-centered prostate biopsy report in clinical prostate cancer practice.. Journal of Clinical Oncology, 2018, 36, 145-145.	1.6	1
202	Increasing use of neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC): Prognostic impact of non-standard of care (SOC) regimens.. Journal of Clinical Oncology, 2019, 37, 4532-4532.	1.6	1
203	Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, 372-372.	1.6	1
204	Association of chemotherapy regimen with venous thromboembolic risk in patients with urothelial tract cancer.. Journal of Clinical Oncology, 2017, 35, 314-314.	1.6	1
205	Impact of cytoreductive nephrectomy on timing of systemic therapy in metastatic kidney cancer.. Journal of Clinical Oncology, 2017, 35, 503-503.	1.6	1
206	Small cell bladder cancer: Treatment patterns and clinical outcomes.. Journal of Clinical Oncology, 2020, 38, e17014-e17014.	1.6	1
207	The impact of telemedicine on patient-reported outcomes in urologic oncology.. Journal of Clinical Oncology, 2020, 38, e14154-e14154.	1.6	1
208	Sarcomatoid urothelial carcinoma (SUC): A single-institution experience of oncologic outcomes and recurrence patterns.. Journal of Clinical Oncology, 2020, 38, 465-465.	1.6	1
209	Reply by Authors. Journal of Urology, 2022, , 101097JU0000000000000235002.	0.4	1
210	Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer. Journal of Urology, 2022, 207, 496-497.	0.4	1
211	Editorial Comment. Journal of Urology, 2012, 187, 66-67.	0.4	0
212	Why Does Anyone Get Shock Wave Lithotripsy?. JAMA Surgery, 2014, 149, 654.	4.3	0
213	Introduction. Surgery, 2014, 155, 731.	1.9	0
214	More Is More: Disentangling the Importance of Ejaculation Frequency. European Urology, 2016, 70, 983-984.	1.9	0
215	Prostate cancer screening: Do guidelines matter?. Cancer, 2016, 122, 3760-3761.	4.1	0
216	Improving Quality in Renal Cell Carcinoma Care: Bridging the Gap Between Measurement and Meaning. European Urology, 2017, 72, 387-388.	1.9	0

#	ARTICLE	IF	CITATIONS
217	Urinary Catheter Management for Nonurologists: A Resident Driven Educational Initiative. <i>Urology Practice</i> , 2017, 4, 85-90.	0.5	0
218	High Burden of In-Person Kidney Cancer Surveillance in a Low Resource Population. <i>Urology Practice</i> , 2020, 7, 373-377.	0.5	0
219	Washington State Surgeon Perspectives on Quality Measures in the Surgical Care of Stress Urinary Incontinence in Women. <i>Urology Practice</i> , 2021, 8, 78-81.	0.5	0
220	COVID-19 Seminars Issue 2 – Introduction. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, , .	1.6	0
221	Editorial Comment. <i>Journal of Urology</i> , 2021, 206, 238-238.	0.4	0
222	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 912-920.	2.1	0
223	Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4540-4540.	1.6	0
224	Twenty-year trends in survival for metastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 454-454.	1.6	0
225	A novel tool to predict outcomes following radical cystectomy using age and co-morbidity status.. <i>Journal of Clinical Oncology</i> , 2015, 33, 354-354.	1.6	0
226	Need to travel for urologic care: The impact of insurance.. <i>Journal of Clinical Oncology</i> , 2015, 33, 396-396.	1.6	0
227	Improving the value of PSA prostate cancer screening with “smarter” strategies and increased use of active surveillance.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6616-6616.	1.6	0
228	Utilization and sequencing of targeted therapy and cytoreductive nephrectomy in non-“clear cell metastatic kidney cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 615-615.	1.6	0
229	Comparative effectiveness of a patient centered pathology report for bladder cancer care.. <i>Journal of Clinical Oncology</i> , 2016, 34, 420-420.	1.6	0
230	Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.. <i>Journal of Clinical Oncology</i> , 2016, 34, 607-607.	1.6	0
231	Travel Burden and the Direct Medical Costs of Urologic Surgery. <i>Journal of Health Economics and Outcomes Research</i> , 2016, 4, 47-54.	1.2	0
232	Beyond classical risk adjustment: Socioeconomic status and hospital performance in urologic oncology.. <i>Journal of Clinical Oncology</i> , 2017, 35, 526-526.	1.6	0
233	Nationwide disparities in testicular cancer care delivery: Racial, ethnic, and economic markers of patient vulnerability.. <i>Journal of Clinical Oncology</i> , 2017, 35, 421-421.	1.6	0
234	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-24.	1.6	0

#	ARTICLE	IF	CITATIONS
235	CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making.. Journal of Clinical Oncology, 2017, 35, 527-527.	1.6	0
236	Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.. Journal of Clinical Oncology, 2018, 36, 72-72.	1.6	0
237	Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?. Journal of Clinical Oncology, 2019, 37, 441-441.	1.6	0
238	Bladder Cancer Multidisciplinary Clinic (BCMC) model: Impact on imaging, pathology and treatment recommendations.. Journal of Clinical Oncology, 2019, 37, 4537-4537.	1.6	0
239	Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, e16021-e16021.	1.6	0
240	Editorial Comment. Journal of Urology, 2019, 202, 524-524.	0.4	0
241	Intravesical therapy and risk of cystectomy and bladder cancer death after BCG fails.. Journal of Clinical Oncology, 2020, 38, e17026-e17026.	1.6	0
242	Perioperative blood transfusion and postoperative outcomes in patients undergoing radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2020, 38, e17012-e17012.	1.6	0
243	Associations between baseline body composition and cancer-specific mortality following neoadjuvant chemotherapy and radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2020, 38, e17015-e17015.	1.6	0
244	Editorial Comment. Journal of Urology, 2020, 203, 1007-1007.	0.4	0
245	Skeletal muscle index and adverse events during a bladder cancer treatment episode.. Journal of Clinical Oncology, 2020, 38, e17016-e17016.	1.6	0
246	Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study.. Journal of Clinical Oncology, 2020, 38, e19157-e19157.	1.6	0
247	Sarcomatoid urothelial carcinoma: Oncologic outcomes from a tertiary center and SEER-Medicare data.. Journal of Clinical Oncology, 2020, 38, e17033-e17033.	1.6	0
248	The impact of age on general and bladder cancer-specific quality of life among bladder cancer survivors.. Journal of Clinical Oncology, 2020, 38, 463-463.	1.6	0
249	Gender and quality of life in bladder cancer.. Journal of Clinical Oncology, 2020, 38, 464-464.	1.6	0
250	Cancer stage and quality of life in bladder cancer.. Journal of Clinical Oncology, 2020, 38, 466-466.	1.6	0
251	Micropapillary urothelial carcinoma (mpUC): A comparative analysis of oncologic outcomes compared to conventional urothelial carcinoma (CUC).. Journal of Clinical Oncology, 2020, 38, 459-459.	1.6	0
252	Improving the impact of clinical documentation through patient-driven co-design: experiences with cancer pathology reports. BMJ Health and Care Informatics, 2020, 27, .	3.0	0

#	ARTICLE	IF	CITATIONS
253	Longitudinal screening for depression and anxiety in prostate cancer (PC) and association with disease and treatment factors.. Journal of Clinical Oncology, 2022, 40, 5023-5023.	1.6	0
254	Naloxegol versus Alvimopan for Enhancing Postoperative Recovery following Radical Cystectomy for Bladder Cancer. Urology Practice, 0, , .	0.5	0